JNJ · ISSUER CIK 200406
JOHNSON & JOHNSON
Between Aug 1, 2026 and Oct 29, 2026, 4 JOHNSON & JOHNSON insiders reported $0.00 of open-market purchases and $62.0M of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$62.0MInsider selling
−$62.0MNet open-market
Sep 4, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 202609:08 | Sep 2, 2026 | JNJ | EVP, WW Chair, MedTech | S · Sell | $274.74 | −33,597 | 25,447 | -57% | −$9.2M | ||
| Sep 4, 202609:08 | Sep 2, 2026 | JNJ | EVP, WW Chair, MedTech | M · Exercise | $144.99 | +33,597 | 47,974 | +234% | $4.9M | ||
| Aug 18, 202618:31 | Aug 17, 2026 | JNJ | EVP, WWC. Innovative Medicine | S · Sell | $263.36 | −15,000 | 194,451 | -7% | −$4.0M | ||
| Aug 18, 202618:31 | Aug 17, 2026 | JNJ | EVP, WWC. Innovative Medicine | M · Exercise | $115.67 | +15,000 | 209,451 | +8% | $1.7M | ||
| Aug 14, 202616:35 | Aug 13, 2026 | JNJ | CEO and Chairman of the Board, Director | S · Sell | $261.17 | −123,291 | 275,967 | -31% | −$32.2M | ||
| Aug 14, 202616:35 | Aug 13, 2026 | JNJ | CEO and Chairman of the Board, Director | M · Exercise | $115.67 | +123,291 | 399,258 | +45% | $14.3M | ||
| Aug 7, 202617:50 | Aug 5, 2026 | JNJ | CEO and Chairman of the Board, Director | S · Sell | $258.15 | −48,480 | 275,967 | -15% | −$12.5M | ||
| Aug 7, 202617:44 | Aug 6, 2026 | JNJ | EVP, Chief Legal Officer | S · Sell | $257.00 | −15,918 | 16,994 | -48% | −$4.1M | ||
| Aug 7, 202617:44 | Aug 6, 2026 | JNJ | EVP, Chief Legal Officer | M · Exercise | $131.94 | +9,344 | 32,912 | +40% | $1.2M |